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Abstract
In this Master’s Thesis Research the results can be summarized from two major tasks:

(1) In our first task, we utilized our two protein system (BAG-1 and HSP 70) as part of beta
testing of a computational software 1 that can take three dimensional x-ray crystallography
information about protein complexes and predict the strength of atom –atom interactions
between amino-acid residues Open Contact predicts binding hotspots that can be used to
identify short amino acid chains or peptides that mimic that particular binding segment of the
larger protein. These peptides are called pepidyl-biomimetics. The peptide can potentially act
as an antagonist drug by binding to the hotspot on protein A before protein B of the A-B
complex can form. Two potential peptide candidates were identified. In particular, a helical
peptide was discovered that demonstrated a variety of different types of atom-atom interactions.

(2) Our second task is to experimentally test the helical peptide for its ability to block the binding that
occurs between the 70-kilodalton Heat Shock Protein (HSP-70) and the Bcl-2 Associated Athanogene
(BAG-1) Protein. As reviewed here, the binding between HSP-70 and BAG-1 elicits a cascade of
cellular events that maintain high cancer growth rates and a greatly increased resistance to
chemotherapy. In addition, BAG-1 has been implicated in a number of onco-signal pathways, as
reviewed here, and its inhibition alone is believed to act as an agent against cancer cell growth.

ix

CHAPTER 1. The role of the anti-apoptotic complex of HSP-70/BAG-1 in cancer

1.1 Introduction

One of the many challenges encountered when employing chemotherapeutic strategies that try to
rid the body of cancerous cells is when the tumors themselves develop a resistance to
chemotherapeutic drugs. In this thesis we investigated at the macromolecular protein level one
of the possible root causes of this resistance to chemotherapy, the HSP-70/BAG-1 complex, and
a possible strategy on how to inhibit its formation.
The general flow of this chapter will be to first introduce our two major players in the protein complex
of interest: the 70-kilodalton heat shock protein (HSP-70) and its binding partner, Bcl-2 Associated
Anthanogen (BAG-1). Characteristics of each individual biological macromolecule and its respective
relevance in cancer and cancer therapies will be given. Then an analysis of the behavioral
characteristics and function of the BAG-1/HSP-70 complex will follow. Finally, details on inhibiting the
formation of the HSP-70/BAG-1 complex will be considered with respect to increasing the efficacy of
anticancer therapies. Specifically, we will highlight the use of peptides and other inhibitory compounds
that block the complex’s formation in cancer cells and the subsequent reduction that occurs in the
cancerous tumor cells’ ability to defend against chemotherapeutic agents, the decrease of cancer cell
growth rate and tumor size, and the initiation and execution of the process of triggered cell death known
as apoptosis.
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1.2 The Cellular Function of BAG-1
The Bcl-2 Associated Anthanogen (BAG-1) comes from a family of BAG proteins that participate in a
crucial cornucopia of cellular activities such as cellular stress response, cell growth, migration, and the
programmed cellular self-destruct process of apoptosis. BAG-1 was originally discovered by 2 in the
search for B-cell lymphoma 2 (Bcl-2) protein binding partners that were responsible for anti-apoptotic
behavior. What is evolutionarily conserved and distinguishing about the BAG family of proteins is a
sequence of amino acids, a domain, of about 110 residues in length near their carboxyl terminuses. This
domain is responsible for the binding activity that we see in complexes made between BAG-1 and both
the 70 kilodalton heat shock cognate/protein (HSC70/HSP70) family of molecular chaperones as well as
the anti-apoptotic protein Bcl-2 that are implicated in the cellular response to chemotherapeutic stress.
The specific three dimensional amino acid structure of the BAG domain has been determined by x-ray
crystallographic and nuclear magnetic resonance studies to be three anti-parallel α-helices. Now,
although all three of these helices constitute the conserved region of the BAG family of proteins, only
the second and third helices are active in the binding that takes place between BAG-1 and HSP-70.
Specifically, the second and third α-helices of BAG-1 bind to the amino-terminal ATPase domain of the
HSP-70 molecular chaperone. 3. Now that the specific chemical site on BAG-1 that is responsible for its
physiological activity has been identified, let us now turn to identifying some of the roles that BAG-1
interactions play in cancer.
The root cause of the importance of BAG proteins in cancer pathways is they enable the cells to resist
any influence that might otherwise trigger cell death. Hence, it creates a resistance to apoptotic stimuli.
These specific chemical signaling pathways are related to the attachment of ubiquitin and the resulting
proteolytic degradations that may occur in the tumor suppressor p53 and some cyclins. 2. Therefore, this
11

resistance to apoptotic stimuli in cancer cells that is enabled by the BAG family of proteins makes
chemotherapy less effective and therefore requires that cancer patients endure higher doses of and more
side affects from chemotherapeutic agents while benefiting less from the treatments. The general
direction and overall long term objective of this research is to demonstrate that inhibiting BAG proteins
will lower cells’ resistance to stress and help magnify apoptotic pathways vital to successful
chemotherapy treatments. This thesis is meant to investigate the initial step of finding a molecule that
can inhibit BAG-1 by binding to it. In addition to HSP 70 interactions, over-expression of BAG proteins
in cancer cells stimulates cell growth in tumors through interaction with the serine/threonine kinase Raf1 4. Raf proteins function in the MAPK/ERK signal transduction pathway that regulates the cell cycle. In
the work by 5 they also suggest that BAG-1 can control the rate at which cells proliferate by binding to
and reducing the activity of Raf-1. This suggests that BAG-1 may be a molecular control for cell
growth.
The multiple roles of BAG in cancer are considered important in this research because it shows
inhibiting BAG maybe two-fold: first reduce a tumor’s resistance to apoptotic stimuli and make
chemotherapy more affective against tumors and second, potentially inhibit the rate of tumor growth.
Now that we have identified the two pertinent roles that BAG-1 plays in cell function, we shall now take
a closer look at the specific types of cancer cell lines that BAG-1 proteins have been most abundantly
over-expressed and suspected of playing a role in.
1.3 BAG’s specific role in cancer.
To further investigate the role of BAG-1 in cancer, a common approach is to identify a specific gene and
its expressed protein and then remove the gene from a given cell line and observe what changes occur in
the delimited cell line as compared to the original line’s behavior. When 6 used this approach on ZR-7512

1 breast cancer cells via transfection with mutants of BAG-1 that were missing the evolutionarily
conserved BAG domain it was observed that the resultant tumors that contained the deficient mutant
genes grew more slowly and were smaller as well. They then further demonstrated breast cancer’s
dependence on the BAG-1 protein for cell growth and survival using the following experimental
methodology.
The control group used wild type ZR-75-1 cells as the baseline for cancer cell behavior, while there
were two experimental groups of cancer cells. The first experimental group was wild type cancer cells
transfected with BAG-1 encoding expression plasmids to up the amount of BAG-1 produced, while the
second experimental group was made of breast cancer cells that were transfected with BAG-1 mutants
that contained a modified BAG gene that produced a BAG-1 protein that lacked the C-terminal domain
that HSP-70 binds to. The experiment used both ZR-75-1 experimental and control cells that were both
cultured in vitro as well as injected into the mammary fat pads of mice to create tumor xenografts. In the
cell cultures, the necessity of BAG-1 in the stress response of cells under challenging conditions was
demonstrated by showing that the mutant cancer cells lacking the BAG domain died when cultured
without serum whereas the control and BAG enhanced experimental groups survived for over seven
days. The same serum deprivation also failed to induce caspase protease activation in the control group,
whereas not only did the BAG deficient experimental group experience it but the sensitivity to
anchorage dependence was also partially restored as well.
The caspase protease activation is important because it is the executionary arm of the signaling pathway
of apoptosis. There are numerous ways to inflict cellular stresses that lead to apoptosis, but regardless of
where the internal or external stresses came from once the cysteine proteases called caspases are
activated then cell death is imminent. Serum deprivation was chosen to inflict the potentially fatal stress
13

simply because it was convenient to the design of this experiment. BAG-1 inhibits apoptosis by
inhibiting caspase protease activation. If there is no BAG-1 and caspase protease activation occurs as in
the BAG-1 deficient experimental group, then the cells die.
The anchorage dependence is relevant to cancer because it is the quantifier of metastasis’ ability. The
less dependent a cancer cell is on anchorage, the easier it is for the cell to metastasis to other parts of the
body. The BAG-1 present in the control and BAG-1 rich experimental groups allows for easier
movement and metastasis, whereas the BAG deficient experiment group was more anchorage dependent
and hence could not metastasis as easily. It was also observed that the BAG deficient experimental
group exhibited retarded growth rates.
These in-vitro observations show that in general the BAG domain regulates growth rates as well as
several different stress response pathways in breast cancer and that these cancer cells will grow slower
and perish under stress without it.
In regards to the tumor xenografts in mice, further support for the role of BAG-1 in tumor growth rates
was found when the BAG enhanced tumors grew to roughly 150% of the size of the control group
tumors, whereas the BAG deficient tumors grew very slowly and only reached 33% of the size of the
control group. Altogether, 6 have demonstrated that BAG-1 protein expression plays a crucial role in the
growth rates and survival capability of ZR-75-1 human breast cancer cells. Breast cancer however is
only one of the many cancers that BAG-1 plays a prominent role in.
It has been shown by 7 that another member of the BAG family, BAG-3, plays a role in regulating the
progression of thyroid cancer. It is important to note that the BAG gene leads to six different human
BAG proteins, and four out of the six (BAG-1, -3, 4, & -6) have been shown to interact with HSP-70.
When we specifically target the coiled coil structure of approximately 110 amino acids consisting of
14

three anti-parallel alpha helices at the carboxyl terminus that is the chemical binding hot spot on the
protein in the BAG protein family known as the BAG domain, it is important to notice that although the
different members of the family have different weights and hence the hot spot BAG domain may be
located in different places in each respective protein, it is still the same evolutionarily conserved
sequence of 110 amino acids that makes up the BAG domain that is responsible for all of the
physiological activity of the entire BAG family of proteins in cancer pathways. Therefore, if you can
find a way to inhibit this cancerous physiological activity by binding something to the BAG domain of
any given BAG protein so that it can’t interact with any other proteins in the cancer pathway, in theory
that inhibitor should be effective at inhibiting not just that one member but every isoform of the entire
BAG family of proteins as a whole because it is the amino acid sequence that is common to all of them
that is being targeted. The image below shows the conserved BAG domain as expressed throughout the
family.

15

Figure 1.3-1 Expression of the BAG domain throughout the BAG family 3

Therefore, any inhibitor that could down-regulate the BAG-3 in thyroid cancer should hypothetically be
effective against the BAG-1 in breast cancer as well.
The next type of cancer that BAG-3 shows up in is prostate cancer. In the immunohistochemical
analysis done by 8 on prostate carcinomas that were surgically removed, all 55 samples contained
elevated levels of BAG-3 in the cytoplasm. In the work done by 9 they show that BAG-3 directly
16

regulates the triggered cell death process of apoptosis in a specific type of blood cancer known as Bchronic lymphocytic leukemia. In addition to Romano et al, 10 have also shown that BAG3 has the
ability to regulate apoptosis in both normal and neoplastic leukocytes.
Another example of BAG-3’s role in cancer was found by 11 in glioma, a type of caner that starts
in the glial cells of the neck and spine. Between the benign and malignant forms, one of the most
aggressive malignancies is named Glioblastoma multiforme, and it represents 80% of the cases of
malignant brain cancer. It is a particularly difficult type of cancer to treat because it is incredibly
aggressive and has a very high rate of recurrence. One of the interesting things that Festa et al found that
further elucidates BAG-3’s role as a therapeutic target in cancer is that while there were no traces of
BAG-3 in healthy cells, cancerous cells not only had BAG-3 in them but it was also found that the more
aggressive the cancer, the higher the concentrations of BAG-3 that were found in the tumor cells. The
group further demonstrated that when BAG-3 was down-regulated in both cell cultures and in rat test
subjects where the rats had glioblastoma that the cancer cells had an increased sensitivity to apoptosis,
further suggesting BAG-3’s role as a therapeutic target for cancer treatments. The group also noted that
BAG-3 had to combine with both HSP-70 and bcl-2-Associated X Protein (BAX) in order to stop
apoptosis by preventing BAX from translocating to the mitochondria. This is further mechanistic
evidence suggesting that a BAG-3 inhibitor could up-regulate apoptosis by getting BAX to the
mitochondria by protecting it from being bound to the HSP-70/BAG-3 complex before it can do its job
of triggering cell death in tumors.
The final type of cancer we will explicitly examine in this work that highlights the presence of
BAG proteins in cancer pathways is for that of pancreatic cancer. 12 have shown that both the cytosolic
and nuclear forms of BAG-1 have been found as over-expressed in adenocarcinoma of both the head and
17

periampullary regions of the pancreas. The work done by 13 has further elaborated on the role of BAG
proteins in pancreatic cancer by showing that in pancreatic cancer cells BAG-3 mRNA was moderately
to severely over-expressed in all cancer cells analyzed. This group also went on to suggest the BAG-3
was involved in blocking apoptosis in this line of cancer cells as well.
In summary of the role of BAG proteins in cancer pathways, we have shown that the common
role of BAG-1 and BAG-3 over-expression in thyroid, breast, prostate, leukemic, brain, and pancreatic
cancers all relate to the cancer cells’ ability to block the apoptotic process of triggered cell death and
enhance the cells’ respective tumor’s ability to resist and survive chemotherapy. These studies
demonstrate that the BAG domain of the BAG family of proteins is a novel anticancer therapy target.

1.4 HSP-70
An increasing number of oncological research papers that examine the biochemical make-up of
surgically extracted tumors have come to the conclusion that tumors and cancer cells in general are
“addicted” to stress proteins 14. In the previous section we examined the Bcl-2-associated anthanogen
protein family (BAG family of proteins) and it was quite apparent that the majority of those papers did
not examine BAG-1 and BAG-3 alone, but more instructively looked at the protein complexes that the
aforementioned proteins made with other molecular chaperones in the establishment of the cancerous
resistance to apoptotic stimuli. One of the most commonly mentioned chaperone protein partners
mentioned was that of the Heat Shock Family of molecular protein chaperones (HSP’s).
If cancer were a runaway train, it would be important to notice that the root cause of the problem is both
an accelerator that is stuck to the floor as well as brakes that are malfunctioning. Analogously, in cancer
the ability to promote autonomous cell proliferation is the accelerator being stuck to the floor
18

(oncogenes), and the ability to inhibit cellular death pathways is the defective brakes (faulty tumor
suppressor genes). The presence and over-expression of heat shock proteins in cancer cells is in at least
part of what gives cancer its ability to exhibit the aforementioned traits. What gives rise to the excess of
HSP’s in cancer in the first place is the absence of p53 function coupled with increased transcription of
the cancer promoting genes HER2 and c-Myc

15

.

The HSP human genome superfamily of proteins is distinguished by their different characteristic
molecular masses, where the most commonly studied superfamily members are the 10, 27, 40, 60, 70, 90
and 110-kilodalton mass members 15. Inside of each of those mass specified superfamily members are
different phenotypes of the same general mass of protein. For our specific research we will examine the
70-kilodalton heat shock protein family member. The four major phenotypes of proteins from the HSP70 superfamily that are of greatest importance are the heat shock cognate HSC70 that is constitutively
expressed, GRP70 that is found in the endoplasmic reticulum, mtHSP70 from the mitochondria and
finally the stress-inducible HSP70 that we are specifically studying in this research and will just refer to
as HSP-70 14. Just as in the previous section we examined how BAG-1 and BAG-3 played roles in
various types of cancer, we shall now analogously examine HSP-70’s oncologic relevance.
In the work done by 16 they simultaneously studied the effects of HSP-70 depletion in brain, breast, and
colon cancer. The work was done in vivo using xenografts of the respective types of cancers on
immunodeficient mice, and the inhibition of HSP-70 that equivalently resulted in its depletion was
accomplished using an HSP-70 antisense expressing adenovirus that was locally injected into the
tumors. The result was that not only did the injections induce massive amounts of apoptosis-analogous
cell death, but they simultaneously incurred the recruitment of human monocyte-derived macrophages to
remove the remains of the self destructed cells. Therefore, in all three types of this cancer, HSP-70
19

played such a crucial role in the tumor’s ability to survive that the moment HSP-70 wasn’t there
anymore the cancer cells not only self destructed but monocytes then showed up to clear out the cellular
corpses left behind. This shows how potent of a weapon against cancer that HSP-70 inhibitors can be.
17

were able to further demonstrate the anticancer capabilities of HSP-70 inhibition by suppressing HSP-

70 expression via inhibition of its transcription factor HSF1. This resulted in sensitizing to
chemotherapy a cell line of pancreatic cancer that had previously exhibited drug-resistance to
chemotherapeutic agents. It has also been shown that inhibition of HSPs can increase the effectiveness
of cancer hyperthermic therapy in treating colon cancer 18.
In addition to its presence in brain, breast, colon, and pancreatic cancers, 19have shown HSP-70’s role in
the skin cancer melanoma, 20 demonstrated its importance in acute myeloid leukemia, and 21 have also
identified HSP-70’s role in breast cancer .

1.5 BAG-1/HSP-70 complex attributes and inhibition
Both HSP-70 and BAG-1 protein have been identified as major protein players in a cornucopia of
different types of cancers. It is also important to note that the term ‘chaperone’ or ‘co-chaperone’ always
appears in the literature pertaining to these two compounds, and that it’s never one pure protein that
plays a role in the cancer’s progression nearly as much as it is a pair of proteins where one assists or
chaperones the other one’s function. With both HSP-70 and BAG-1 being involved in anti-apoptotic
processes in cancerous tumors cells, the complex they form together greatly magnifies the each protein’s
respective cellular functions. Therefore, inhibiting this complex is of great interest in the pursuit of
increasing the effectiveness of chemotherapeutic agents.
In general there are several pathways that the HSP-70/BAG-1 complex plays a role in however, as 6
20

have pointed out that the complex regulates a wide ranging set of pathways involved in cell growth,
death, and stress responses. It is because this complex plays such a crucial role in so many different
cellular growth and death pathways, and gives cells the ability to persevere under stressful environments
that would have otherwise killed the cells that didn’t have this complex in them, that it is such an
important task to disrupt this complex. Each protein on its own contributes to the accelerated growth and
resistance to stresses that make certain cancers so hard to treat, and when they join together as HSP70/BAG-1 they could quite possibly be the main molecular workhorse that protects tumor cells from
chemotherapy. The question addressed below is how to effective inhibit the formation of the HSP70BAG . To answer this we turn to a computational approach based on the design of peptide biomimetics.

21

CHAPTER 2. Inhibiting Protein-Protein Interactions

2.1 Peptidyl-biomimetics
Protein-protein interactions that underlie cancer signal pathways are a promising avenue for the
development of inhibitory compounds aimed at disrupting cancer networks. Specifically, small peptide
inhibitors that mimic the protein segments associated with specific residue-residue interactions
(peptidyl-biomimetics) in native, cellular processes have shown success as therapeutic agents 22;

23

. In

this study we utilize a static, contact mapping algorithm (Open Contact) capable of predicting
quantitative binding information in protein-protein interactions for the optimal design of peptidylbiomimetics. In this work, we apply Open Contact to the binding between the 70 kilo-Dalton heat
shock protein (HSP70) family of molecular chaperones and the Bcl-2-associated athanogene (BAG)family of proteins.

22

Figure 2.1-1 HSP70/Bag-1 Complex. BAG-1 is the coiled-coil structure shown in red.
Current molecular therapeutic approaches to the HSP70/BAG-1 system have been primarily aimed at
disrupting the ATP-ase domain of HSP70

24

, 21. These approaches have yet to be successful 25. Based

on the importance of the multiple roles of BAG in cancer, we take a different systematic, deterministic
approach and examine potential inhibitors to BAG-1 based on development of an HSP 70 petidylbiomimetic.

23

2.2 Open Contact
Open Contact is an open source all atom computational program that predicts atom-atom separation
distances, electrostatic interaction potentials, and Lennard-Jones interaction potentials from existing
Protein Databank Files (.pdb files) on the binding partners. The files are generated using data from x-ray
crystallographic and nuclear magnetic resonance studies that elucidate a three dimensional atomic
structure for a given biochemical compound.
The program can also be used to predict intraparticle protein interactions for the development of
peptidyl-biomimetics aimed at disruption of folded protein states as well as interparticle interactions
between two protein binding partners. Open Contact uses all atom force field constants are based on
AMBER 03 force field model 26.
Beginning with the complete complex structure shown in Fig. 2.1-1 we determined a contact mapping
for atom-atom separation distances less than 10 angstroms, as shown in Fig. 2.2-1 below. The
electrostatic and L-J interaction potential values are (partially) shown in Table 2.2-1 (for brevity).
RESIDUE A
ALA
ALA
PHE
PHE
PHE
PHE
PHE
THR

NUMBER ATOM A NUMBER RESIDUE B NUMBER ATOM B NUMBER
43
C
284
ARG
205
NH1
3327
43
C
284
ARG
205
NH2
3328
44
C
289
ARG
205
NH1
3327
44
C
289
ARG
205
NH2
3328
44
O
290
ARG
205
NE
3325
44
O
290
ARG
205
CZ
3326
44
O
290
ARG
205
NH2
3328
45
N
298
ARG
205
CZ
3326

UCOUL
-3.95E-01
-4.57E-01
-6.88E-01
-1.16E+00
-4.19E-01
-7.54E-01
1.60E+00
-3.29E-01

ULJ
-2.97E-03
-4.90E-03
-1.91E-02
-7.02E-02
-1.83E-02
-4.21E-02
-1.75E-01
-3.77E-02

Table 2.2-1 Example of Atom-Atom Contact Values – the last column are the screened (dimensionless)
Coulombic interaction potentials (relative to kT)

Interestingly for this system, Open Contact identified two potential stable peptide inhibitors to BAG-1.
The first is an approximate 15 residue alpha helix consisting of residues ASN256 through ALA270 and
24

the second is a 17 residue loop structure consisting of residues ALA280 through SER296. Both
structures are strongly stabilized by intramolecular hydrogen bonding as associated with either loop or
alpha-helical motifs and specifically shown in Fig. 2.2-1.

Figure 2.2-1 Parsed, contact mapping of HSP70-BAG-1 complex. Only atom-atom
contacts less than approximately 10 angstroms are shown.
Candidate 1 (code name PEPMH15): ASN256 through ALA270
Candidate 2 (code name PEPML17): ALA280 through SER296
Mathematical modeling of the interactions between the two proteins using MATLAB ® mathematical
software yielded the following plots for atom-atom separation, atom-atom coulombic potential, and
atom-atom Lennard-Jones potentials. These plots assist in the isolation of the binding hotspot that the
peptide is designed to interact with.
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Figure 2.2-2 Atom-Atom Separations less than 10 Å

Figure 2.2-3 Atom-Atom Coulombic Potentials

26

Figure 2.2-4 Atom-Atom Lennard-Jones Potentials

2.3 Objective
. In this research we aim to demonstrate that a stable peptide inhibitor can show excellent potential as a
therapeutic agent aimed at disrupting HSP70/BAG-1 complexes. The peptide will be specifically
chosen to disrupt the hydrogen bonding that occurs between the two proteins at its area of strongest
interaction, its hotspot or binding domain. For this specific complex, we have chosen to target the
hotspot region identified as Candidate 1 (code name PEPMH15): ASN256 through ALA270.
Our hypothesis is that we can verify via Biacore binding assays that by binding the synthetic peptide
PEPMH15 to the ASN256-ALA270 region of the BAG-1 protein, we can competitively inhibit HSP-70
from binding to and complexing with the BAG-1 protein and thereby achieve the goal finding a
molecule capable of inhibiting the chaperone activity of BAG-1 in the HSP-70/BAG-1 complex.
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CHAPTER 3. The Role of Biacore Kinetics Binding Assays

3.1 Biacore Models the Binding that Occurs in Cells
The role that Biacore binding assay analysis will play in our research is that it will enable us to
conduct label-free kinetic analysis of the binding that occurs between the therapeutic peptide candidate
(code named PEPMH15) and the protein of interest BAG-1. The most important aspect of the binding of
the peptide to the protein isn’t just that it binds, but it stays bound. The peptide PEPMH15 needs to
continuously stay in place and remain bound to BAG-1 over time in order to make sure that the
chaperone protein HSP-70 doesn’t have an opportunity to bind to the BAG-1. The determination of the
“on-rates” and “off-rates” of PEPMH15 are described below.

3.2 Biacore Kinetics: On Rates, Off Rates, and Equilibrium Dissociation Constants
In mentioning that the peptide doesn’t just have to bind but stay bound to the protein, what we are really
discussing in kinetic terminology is the measurement of the on and off rates of the peptide. If the on-rate
is the same as the off-rate, then just as soon as one peptide binds then another already bound one
detaches from the protein. This equivalence between on and off rates is the same as no net binding
occurring, so that the BAG-1 protein is still effectively free to bind to HSP-70.
The second possibility of the off-rate between larger than the on-rate is also the equivalent of no net
binding because it is easier for a peptide to come off of the protein than it is to bind onto it, so that
effectively no peptides stay on long enough to block the HSP-70 from binding.
The third scenario, which is the one we hope the Biacore Assays will demonstrate, is that the on rate is
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larger than the off rate, so that it is an easier and faster process for the peptide to bind to the protein than
it is to unbind, which produces a net positive amount of binding so that enough peptides stay bound to
the BAG-1 so that it is possible to block the binding of HSP-70 and effectively inhibit the HSP70/BAG-1 complex from forming in the first place.
Kinetically it is important to note that if the reaction is written as in figure 3.2-1 where the peptide is A
and the protein is B, then the on rate is the association rate constant ka and the off rate is the dissociation
rate constant kd.

figure 3.2-1 Balanced equation for the binding reaction
With this model in place, we can now define the Dissociation affinity constant as KD = kd/ka. It is
important to notice though that kinetically this is different from an equilibrium constant, because an
equilibrium constant if forward rate over reverse rate, but the dissociation affinity constant has the
revere rate in the numerator and the forward rate in the denominator, so it is equal to the inverse of the
equilibrium constant. The convention came about because it is really the off rate that determines whether
or not an inhibitor can stay bound long enough and in high enough concentrations in order to be viable.
Therefore, if we desire a system where the off rate kd is relatively small and the on rate ka is
comparatively large, then a desirable binder should have a small dissociation affinity constant KD, such
that it is in the nanomolar (nM) range. It has been determined by 27 using both isothermal titration
microcalorimetry and surface plasmon resonance that the KD for the HSP-70/BAG-1 complex is in the
100nM range.
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3.3 Kinetic Goals of the Experiment
In order for our peptide PEPMH15 to function effectively as an inhibitor to this complex, the KD for the
binding between PEPMH15 and BAG-1 has to be either equal to or less that the KD for the complex’s
binding in order for the peptide to win the competitive binding race against HSP-70 for the binding
hotspot on BAG-1. Therefore, our kinetic goal for this binding assay is to prove that our peptide binds to
BAG-1 with a KD ≤ 100nM.
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CHAPTER 4. Equipment, Materials and Methods

4.1 Equipment
The binding assays will be performed using a Biacore T200 surface plasmon resonance (SPR)
instrument using a CM5 Biacore chip. The instrument is controlled by Biacore T200 control software.
This equipment is all being used through VCU Core Labs’ Flow Cytommetry Division.

4.2 Materials
The three different biochemical materials used in this binding study are the HSP-70 and BAG-1
proteins, and a synthetic peptide codenamed PEPMH15. Both the HSP-70 and BAG-1 were purchased
through ENZO life sciences and the PEPMH15 was purchased through New England Peptide.
The peptide purchased through New England Peptide (NEP) Corporation has the sequence AcNKRAVRRLRTACERAKRTL-amide. It has a calculated average molecular weight of 2340 Daltons
and was confirmed via mass spectral analysis to weigh 2342, which is acceptably within the 0.1% error
tolerance.
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Figure 4.2-1 Mass Spectra of Synthetic Peptide
Purity testing via HPLC on a standard HPLC gradient of water and acetonitrile with a minute amount of
trifluoroacetic acid in it gave a purity by area percent of 96.25% area.

Graph 4.2-2 HPLC chromatogram indicating peptide purity.
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The human recombinant HSP-70 was produced in E. Coli and came in a liquid formulation of
25mM HEPES/KOH at pH 7.6, containing 100mM potassium chloride, 5mM magnesium dichloride,
10mM b-mercaptoethanol, 1mM EDTA and 5% (v/v) glycerol. Its concentration was 2mg/mL, its purity
was greater than 95%, and its molecular weight was 70 kilodaltons.
The human recombinant BAG-1 was produced in E. Coli and came in a liquid formulation of 20mM
TRIS‐HCl, pH 7.5, containing 100mM sodium chloride, 1mM DTT, and 1% glycerol. Its
concentration was 0.5 mg/ml, its purification was performed by multistep chromatography, its purity
was verified via SDS-PAGE and Western blotting to be greater than 80%, and its molecular weight was
46 kilodaltons.
The CM5 chip purchased from Biacore GE Healthcare (through Core Labs) consists of a surface
matrix of carboxymethylated dextran that is covalently bound to a gold surface. The ligand molecules
from one half of the complex that one wishes to study can then be covalently coupled to the sensor
surface via amine, thiol, aldehyde or carboxyl groups. Due to the chip’s high binding capacity it tends to
give a high response in terms of resonance unit change, which is advantageous for interactions involving
small molecules such as the peptide drug candidates that we wish to study. Because the CM5 chip has a
high surface stability it allows for very accurate and precise measurements of binding events on the
surface, and it also allows for repeated analysis on the same surface through regenerative techniques (to
be addressed in the next section). All of these features of the CM5 chip allow us to couple the BAG-1
protein to the dextran matrix of the chip and effectively immobilize it to the sensor surface via amine
coupling of the Protein’s -NH2 groups. Every time an assay is run and an analyte (HSP-70 or Peptide) is
bound to the BAG-1 on the surface, the analyte can then be ‘washed off’ and the surface regenerated and
reused for binding studies of multiple types of analytes at a variety of different concentrations.
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The chemical kit used to activate the surface of the CM5 chip and bind the BAG-1 ligand to the
chip’s surface is called an Amine Coupling Kit. It consists of 750 mg 1-ethyl-3-(3dimethylaminopropyl) carbodiimide hydrochloride (EDC), 115 mg N-hydroxysuccinimide (NHS), 10.5
ml 1.0 M ethanolamine-HCl pH 8.5. There is also a regeneration solution from Biacore GE Healthcare
as well.
4.3 Methods and Results
The general strategy employed for using a Biacore System with a CM5 chip is to first insert the
chip into the Biacore and establish a flow of running buffer through the four parallel channels on the
surface of the chip. Then, one channel at a time, the dextran surface of the chip is activated by a mixture
of EDC and NHS. This activates the dextran matrix surface of the CM5 chip so that it is capable of
permanently binding the next analyte that flows through the channel to its surface. At this point it is
important to note that channels one and three were used as ‘blanks’ that had no analyte bound to them,
whereas channels two and four have the ligand bound to there surface. This is so that the SPR signals
from the blanks can be subtracted from the SPR signals of the active channels (one from two and three
from four) so that buffer effects and non-analyte binding events can be ignored by subtracting them out.
Therefore, channels one and three are activated with EDC and NHS, and then have their active sites
sealed off and closed by an injection of ethanolamine. For channels two and four however, once the
channels’ surfaces have been activated then BAG-1 that has been dissolved and diluted in buffer
solution is injected into the running buffer so that as it flows over the sensor chip’s surface the BAG-1’s
amine groups covalently bond to the dextran surface via amine coupling and become (ideally)
permanently attached to the chip. Then, once the proper amount of ligand has been immobilized to the
sensor surface, ethanolamine is then injected into the running buffer to seal the chip’s surface by
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deactivating the remaining active sites on the chip so that any future analytes that are injected into the
running buffer can only bind to the BAG-1 and not the dextran.
Once the BAG-1 had been successfully immobilized to the sensor surface then the next step was
to ensure that the BAG-1’s binding pocket was still active after the amine coupling to the dextran
matrix. To test this, several injections of HSP-70 were made into the running buffer which subsequently
produced the following binding curve and confirmed that the BAG-1 binding domain was still active.

Figure 4.3-1 Three consecutive injections of HSP-70 and then regeneration solution over the surface of
the CM5 chip channel with immobilized BAG-1 protein

The rapid on-rate and stabilization of bound analyte after the injection ceased that is represented by the
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slowly decreasing almost horizontal line after the spike that is higher than the initial baseline by 477
resonance units in the first injection shows that the HSP-70 had indeed bound to the BAG-1 protein and
that the BAG domain binding pocket was therefore still active. The two subsequent injections had
comparable responses as well.
After the first control injection of HSP-70, an injection of regeneration solution was used to
remove the bound HSP-70 from the surface of the chip while still preserving the amine coupled BAG-1
to the dextran surface. We can tell that all of the HSP-70 (or any analyte for that matter) has been
removed from the ligand on the sensor surface because the SPR reading goes back down to the original
baseline level that was initially achieved after the BAG-1 had first been coupled to the chip. This
process was repeated twice for a total of three HSP-70 control injections to verify that the surface was
active and that there was reproducibility of binding behavior.
Once the analyte from the control injection had been removed from the ligand and the surface
regenerated, the next injection was of the peptide to verify its binding affinity for the BAG-1 ligand. The
peptide also bound to the BAG-1, as demonstrated by the binding curve below. (Figure 4.3-2)
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Figure 4.3-2 labeled Sensorgram of HSP-70 control and peptide analyte injections
It is important to notice that the decay curve for the HSP-70 is steady and almost horizontal,
confirming that it is a strong nanomolar binder and is stably bound to the BAG-1 on the surface of the
chip. The peptide however has both rapid on and off rates, and due to the shape of its decay curve it is
evident that it is not as strongly bound to the BAG-1 surface as the HSP-70 is.
Now because the objective of the experiment was to demonstrate that the peptide could inhibit HSP-70
from binding to the BAG-1, after the surface was regenerated with two regeneration solution injections
then another injection of peptide was made to saturate the free ligand sites on the surface of the chip, and
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then an injection of HSP-70 was made to test whether the peptide could inhibit HSP-70 from binding, as
is shown in series 2 in the middle of the full sensorgram below.

Figure 4.3-3 Full sensorgram of inhibition attempt using in-series injections
When more HSP-70 was injected onto the chip once the peptide inhibitor was already bound
(series 2), their signals actually seemed to add to one another. If it were a successful inhibition then once
the peptide were bound then any addition injections of HSP-70 should not cause additional increases in
resonance signal, but because these additional injections of HSP-70 did increase the signal then we have
to explore the possibility that the HSP-70 and peptide might be binding to different sites.
In addition to inhibiting the HSP-70 with the peptide, it was also examined to see if the HSP-70 could
inhibit the peptide, and the same additive effect was encountered indicating that it could not be
conclusively demonstrated that competitive binding was taking place between the peptide and HSP-70,
and hence there was no inhibition. It is clear that the peptide can definitely bind to the BAG-1, but it just
hasn't been shown to be able to competitively bind and inhibit the HSP-70 at the same binding pocket.
In a second experimental design attempt to verify inhibition, instead of consecutively closely spaced
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injections where the analyte from the first injection was decaying off as the second was being injected
into the system, mixtures of the HSP-70 and peptide were injected into the chip in 1:1, 1:2, 1:10, and
1:20 (HSP-70:Peptide) molar equivalences to see if there would be binding that way as well.
Hypothetically, this way both the HSP-70 and peptide have access to the active BAG-1 binding sites at
the same time, and which analyte bound first could be determined by the shape of the decay curve. If it
was a slow and steady almost horizontal decay it was HSP-70, and if it was a quick and rapid concave
up curved decay then it was. However, because the two analytes can bind simultaneously and have an
additive effect, we cannot say for sure whether it was all peptide or a mix of peptide and HSP-70, as
shown below.

Figure 4.3-4 Injections of peptide/HSP-70 mixtures in varying concentrations
Kinetics Data was then obtained via the Biacore Kinetics Wizards using the binding curves shown
below to obtain an affinity between the peptide and BAG-1 of approximately KD=2.6*10-7 M-1
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Figure 4.3-5 Biacore Kinetics Binding Assays of Peptide at various concentrations binding to BAG-1
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CHAPTER 5. Discussion of Results and Future Work

5.1 Discussion of Results
The ultimate objective of the work is to show via Biacore Binding Assays that our peptide can
block HSP-70 from binding to BAG-1. The experimental design is set so that after BAG-1 is
immobilized to the chip we confirm that HSP-70 can still bind to BAG-1 so as to verify that the BAG
binding domain is still active, then the HSP-70 is washed off, the peptide is then bound to the BAG-1 on
the chip to saturate all of the BAG binding domain sites, and then HSP-70 is then passed over the chip to
see if any additional HSP-70 can bind once the peptide is already bound. At this point of the experiment,
once the BAG-1 is coated with peptide, if additional HSP-70 can cause an increased resonance response
then the peptide was ineffective as the HSP-70 was still able to bond to BAG-1 and perform is cancerous
chaperone duties. If however, addition HSP-70 causes no change in resonance to the peptide bound
BAG-1 on the chip, then our peptide is an effective inhibitor of HSP-70/BAG-1 complex via
competitive binding with the HSP-70.
The results of the experiments indicate that although the BAG-1 can be successfully bound to the
surface of the CM5 chip and remain active as shown by the successful HSP-70 control injections, and it
can also be shown that the peptide on its own can also successfully bind to the BAG-1, no conclusive
evidence was found that suggests that there is competitive binding between the peptide and the HSP-70,
so that the peptide in its current state is not capable of inhibiting HSP-70 from binding to BAG-1.
A possible source of error in the experiment was a lack of binding activity of the BAG-1 protein
due to possible denaturation incurred due to pH changes and multiple freeze/thaw cycles endured during
when the binding assays were being conducted. It was observed that when HSP-70 was bound to the
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surface of the chip that BAG-1 in solution flowing over the chip exhibited zero net binding to the
surface when compared to the reference. This suggests a lack of activity on the part of BAG-1. A fresh
batch of BAG-1 protein would need to be purchased and possible changes to the experimental procedure
with respect to running buffer composition/pH and sample prep would have to made and the binding
assays rerun in order to verify whether or not BAG-1 activity was indeed reduced due to denaturation or
not.

5.2 Future Work
Due to the fact that it appears that both the peptide and HSP-70 can bind simultaneously to the
BAG-1, an analysis of the analyte that comes off of the BAG-1 surface after regeneration is necessary to
analyze the analyte for structural clues as to how exactly it bound to the ligand, what conformation it
was in and so on to help improve peptide design and inhibitive function.
It would also be potentially fruitful to investigate the synthesis of the ‘D’ enantiomer of the
peptide and verify if it can inhibit the HSP-70 from binding to the BAG-1. This is because most natural
peptides are of the ‘L’ chirality whereas the synthetic ‘D’ enantiomer is not natural and hence is harder
for the cell to digest. This in turn would mean that the peptide therapeutic of the ‘D’ conformation
would be able to circulate longer in the body and hence have a greater therapeutic affect before being
metabolized, compared to the L-peptide being administered in the same dosage.
In addition to appealing to the chirality of the therapeutic peptide to inhibit its premature
metabolism, it would also be worth investigating whether the inclusion of a special type of ester bond in
place of a peptide bond in the peptide could inhibit the peptidase from metabolizing the therapeutic
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agent as well.
With both the chirality and chemical bond methods of inhibiting the metabolism of the peptide
though, the respective candidate peptides would first have to demonstrate competitive binding with and
inhibition of HSP-70 from binding to BAG-1 before it would even be warranted to perform the cell
culture studies necessary to verify the reduced metabolism and extended circulation time of the
therapeutic peptide in the cells.
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Appendices
Appendix A: Full Table of Coulombic and Lennard Jones Interaction Potentials for HPS-70 / BAG-1
interaction
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